Guru Analysis Of Rexahn Pharmaceuticals, Inc. (RNN)

Rexahn Pharmaceuticals, Inc. (NYSE:RNN) enjoyed a 23.53% run-up in share price since hitting record low of $0.85. The stock managed 3.96% rise and now stands at $1.05 as of 01/09/2019. At recent session, the prices were hovering between $1.01 and $1.07. This company shares are 864.76% off its target price of $10.13 and the current market capitalization stands at $40M. The recent change has given its price a -2.21% deficit over SMA 50 and -61.11% deficit over its 52-week high. The stock witnessed -4.55% declines, -39.66% declines and -32.69% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found RNN’s volatility during a week at 7.14% and during a month it has been found around 7.56%.

Rexahn Pharmaceuticals, Inc. (RNN) Top Holders

Institutional investors currently hold around $2 million or 15.1% in RNN stock. Look at its top three institutional owners. Vanguard Group Inc owns $1.12 million in Rexahn Pharmaceuticals, Inc., which represents roughly 2.8% of the company’s market cap and approximately 56.05% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 192,902 shares of the stock are valued at $195 thousand. The third largest holder is Geode Capital Management, Llc, which currently holds $148 thousand worth of this stock and that ownership represents nearly 0.37% of its market capitalization.

Rexahn Pharmaceuticals, Inc. 13F Filings

At the end of September reporting period, 8 institutional holders increased their position in Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by some 36,229 shares, 8 decreased positions by 77,396 and 13 held positions by 1,677,799. That puts total institutional holdings at 1,791,424 shares, according to SEC filings. The stock grabbed 3 new institutional investments totaling 25,292 shares while 4 institutional investors sold out their entire positions totaling 45,146 shares.

Rexahn Pharmaceuticals, Inc. (NYSE:RNN) Insider Trades

Multiple company employees have indulged in significant insider trading. Rexahn Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Ahn Chang Ho has sold 25,000 shares of Rexahn Pharmaceuticals, Inc. (RNN) in trading session dated Apr. 10, 2017. These shares are worth $175,000 and were traded at $7 each. The SEC filing shows that Jeong Tae Heum performed a sale of 31,727 shares. The CFO disposed these shares by way of transaction on Jan. 12, 2015. The company’s shares were given away at $9.1 per share worth to an income of some $288,716 on account of Jeong Tae Heum.

Director, Ahn Chang Ho, sold 31,466 common shares of Rexahn Pharmaceuticals, Inc. (RNN) in the open market. In a transaction dated Jan. 12, 2015, the shares were put up for sale at an average price of $9.1, raking in a sum of $286,341. After this sale, 651,000 common shares of RNN are directly owned by the insider, with total stake valued at $683,550.

In the transaction dated Jun. 12, 2014, the great number of shares disposed came courtesy the Director; Ahn Chang Ho disposed a total of 13,619 shares at an average price of $9.9, amounting to approximately $134,828. The insider now directly owns 731,392 shares worth $767,962.

Rexahn Pharmaceuticals, Inc. (RNN) Analyst Guide

Several analysts have released their opinion on Rexahn Pharmaceuticals, Inc. (NYSE:RNN), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation.